Drugmaker Aquestive Hit With Suit Over FDA Approval Delay
Pharmaceutical company Aquestive Therapeutics Inc. has been hit with a proposed class action accusing it of harming investors by failing to disclose the likelihood that the U.S. Food and Drug Administration...To view the full article, register now.
Already a subscriber? Click here to view full article